摘要
目的:观察紫杉醇联合顺铂(DDP)方案治疗晚期乳腺癌(ABC)及蒽环类耐药性乳腺癌的疗效与安全性。方法:采用紫杉醇联合DDP方案治疗ABC57例(其中含蒽环类耐药性乳腺癌26例)。紫杉醇175mg/m2,静脉滴入,d1(或分为d1、d8);DDP70mg/m2,静脉滴入,d1(或分为d1~d3),加水化、利尿和止吐治疗,21d为1个周期。本组中位化疗周期数为3个。结果:完全缓解6例,部分缓解24例,稳定16例,疾病进展11例,总的有效率52.6%(30/57),26例蒽环类耐药性乳腺癌患者的有效率为61.5%(16/26)。治疗时一般情况较好者疗效(53.5%)好于一般情况差者(23.3%),P=0.045。中位肿瘤进展时间7个月,1年生存率为61.4%,中位生存期为19个月。主要毒性反应为骨髓抑制及胃肠道反应。结论:紫杉醇和DDP联合方案治疗ABC,特别是蒽环类耐药性乳腺癌疗效较好,使用方便,毒性反应较轻。该方案是包括蒽环类耐药性ABC的有效解救治疗方案。
OBJECTIVE: To evaluate the efficacy and safety of chemotherapy of paclitaxel(PTX) combined with cisplantin (DDP) for advanced breast cancer, including anthracycline-resistant advanced breast cancer (ABC). METHODS: 57 patients with ABC(including 26 patients with anthracycline resistant ABC) were treated with combination chemotherapy of PTX and DDP. PTX 17,5 mg/m^2 DDP 70 mg/m^2 were used on day 1 every three weeks. The median number of cycles was 3. RESULTS: The overall response rate was 52.6% with a median time to progression of 7 months. One-year survival rate was 61.4% The response rate in 26 patients with anthracycline-resistant ABC was 61.5%. Patients with good performance statue have higher response rate than those with bad performance statue. The main side effects were gastrointestinal and hematologic toxicities. CONCLUSION: Paclitaxel and cisplantin combination is active in the treatment for ABC expecially for anthracycline-resistant ABC patients with acceptabale toxicity, and may he a thera- peutic alterna"cive after anthraeycline regimen has faild.
出处
《中华肿瘤防治杂志》
CAS
2007年第9期695-697,共3页
Chinese Journal of Cancer Prevention and Treatment
基金
国家高技术研究发展计划(863计划)项目(2004AA2Z3T63)
关键词
乳腺肿瘤/药物疗法
紫杉酚
顺铂
药物疗法
联合
breast neoplasms/drug therapy
taxinol
cisplantin
drug therapy, combination